These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22161785)

  • 1. New insights into molecular mechanisms of sunitinib-associated side effects.
    Aparicio-Gallego G; Blanco M; Figueroa A; García-Campelo R; Valladares-Ayerbes M; Grande-Pulido E; Antón-Aparicio L
    Mol Cancer Ther; 2011 Dec; 10(12):2215-23. PubMed ID: 22161785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.
    Theou-Anton N; Faivre S; Dreyer C; Raymond E
    Drug Saf; 2009; 32(9):717-34. PubMed ID: 19670913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension as a predictive factor of Sunitinib activity.
    Rixe O; Billemont B; Izzedine H
    Ann Oncol; 2007 Jun; 18(6):1117. PubMed ID: 17586751
    [No Abstract]   [Full Text] [Related]  

  • 5. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
    Wolter P; Stefan C; Decallonne B; Dumez H; Bex M; Carmeliet P; Schöffski P
    Br J Cancer; 2008 Aug; 99(3):448-54. PubMed ID: 18665181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
    Tassi R; Baldazzi V; Lapini A; Carini M; Mazzanti R
    Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM; Szczylik C; Rini B
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
    Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
    Motzer RJ; Escudier B; Gannon A; Figlin RA
    Oncologist; 2017 Jan; 22(1):41-52. PubMed ID: 27807302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
    Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
    Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
    Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
    Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
    Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blue toe syndrome and sunitinib.
    Postema PG; Regeer MV; van der Valk PR; Stroes ES; Richel DJ
    Int J Clin Oncol; 2011 Oct; 16(5):574-6. PubMed ID: 21136131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
    Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
    Chu YH; Li H; Tan HS; Koh V; Lai J; Phyo WM; Choudhury Y; Kanesvaran R; Chau NM; Toh CK; Ng QS; Tan PH; Chowbay B; Tan MH
    PLoS One; 2015; 10(8):e0134102. PubMed ID: 26244574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
    Ansari J; Fatima A; Fernando K; Collins S; James ND; Porfiri E
    Oncol Rep; 2010 Aug; 24(2):507-10. PubMed ID: 20596640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
    Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
    J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.